Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma.
Smadar Kahana-EdwinGeoffrey McCowageLucy CainFederica SalettaAysen YukselNicole GrafJonathan KarpelowskyPublished in: Pediatric blood & cancer (2020)
Driver mutations in the CTNNB1 gene (encoding β-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed with localised HBL, with serial sampling along the course of therapy and follow up providing a sensitive mechanism to monitor tumour dynamics and response to treatment. This exciting potential for CTNNB1 ctDNA to serve as a biomarker for treatment response in HBL holds clinical value, and requires assessment in a larger cohort of mixed tumour stages and recurrent disease.
Keyphrases
- circulating tumor
- end stage renal disease
- ejection fraction
- newly diagnosed
- cell free
- prognostic factors
- circulating tumor cells
- epithelial mesenchymal transition
- genome wide
- late onset
- risk assessment
- copy number
- bone marrow
- gene expression
- human health
- cell therapy
- combination therapy
- transcription factor
- early onset